Robex Files Addendum to Information Circular in Connection With Amendment to Arrangement Agreement With Predictive Discovery
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*